A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject

Clinical trial NCT03278470 · COMPLETED

Trial details

NCT number: NCT03278470
Sponsor: Hanlim Pharm. Co., Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Rheumatoid Arthritis

Start date: 2017-06-26
Primary completion: 2018-03-19
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.